Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE)
Source: View publication →
The CREDENCE trial demonstrated that in patients with type 2 diabetes and albuminuric chronic kidney disease, canagliflozin significantly reduced the risk of a composite of end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
CREDENCE provided definitive evidence that SGLT2 inhibitors offer significant renal-protective benefits in patients with type 2 diabetes and chronic kidney disease, transforming the standard of care for preventing progression to end-stage kidney disease when added to maximized RAS inhibition.
Historical Context
Prior to CREDENCE, SGLT2 inhibitors showed consistent cardiovascular benefits in large outcome trials (e.g., EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58), but their direct efficacy in preventing renal disease progression in a dedicated population with established nephropathy had not been prospectively confirmed until this landmark trial.
Guided Discussion
High-yield insights from every perspective
What is the physiological mechanism by which SGLT2 inhibitors like canagliflozin reduce intraglomerular pressure, and why is this protective in diabetic nephropathy?
Key Response
SGLT2 inhibitors block sodium reabsorption in the proximal tubule, increasing sodium delivery to the macula densa. This restores tubuloglomerular feedback, leading to afferent arteriolar vasoconstriction. In diabetes, the kidney is often in a state of hyperfiltration due to afferent dilation; by reversing this, canagliflozin reduces the mechanical stress and barotrauma on the glomerulus, slowing the progression of albuminuria and fibrosis.
In a patient with Type 2 Diabetes and an eGFR of 35 mL/min/1.73m² who is already on a maximally tolerated ACE inhibitor, how should you interpret a 15% drop in eGFR four weeks after starting canagliflozin?
Key Response
Similar to the 'ACE-inhibitor dip,' SGLT2 inhibitors cause an initial functional decline in eGFR (hemodynamic dip) due to the reduction in intraglomerular pressure. In the CREDENCE trial, this was expected and not associated with acute kidney injury. A dip of less than 30% without other signs of volume depletion or electrolyte imbalance is generally considered a sign of successful hemodynamic engagement and should not lead to discontinuation of the drug.
While CREDENCE focused on albuminuric CKD (UACR >300 mg/g), how do these findings integrate with the earlier CANVAS program data regarding the risk of lower-limb amputations and fractures?
Key Response
The CANVAS trial previously raised concerns regarding a potential increased risk of amputations and fractures with canagliflozin. However, CREDENCE—which utilized a similar population but with more advanced renal disease—did not find a significant difference in amputation or fracture rates between the canagliflozin and placebo groups. This suggests that the risks observed in CANVAS may have been due to chance or specific study protocols rather than a class effect or a consistent drug-related toxicity.
How does the CREDENCE trial shift the management paradigm for diabetic kidney disease from 'glucocentric' to 'organ-protective'?
Key Response
For nearly two decades, RAS blockade was the only evidence-based intervention for slowing CKD progression in diabetes. CREDENCE proved that SGLT2 inhibitors provide profound renal and cardiovascular benefits that are largely independent of their glucose-lowering effect (which is minimal at lower eGFRs). This mandates a shift where these agents are prescribed specifically for kidney and heart failure protection, regardless of whether a patient's HbA1c is already at target.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The CREDENCE trial was stopped early following a planned interim analysis by the Independent Data Monitoring Committee. What are the statistical risks associated with early termination for efficacy, and how does the magnitude of the p-value ($p=0.00001$) mitigate these concerns?
Key Response
Early termination can lead to 'the winner's curse,' where the treatment effect size (hazard ratio) is overestimated. However, the extreme statistical significance and the consistency of the secondary outcomes in CREDENCE suggest that the observed 30% reduction in the primary composite endpoint is robust and unlikely to be a result of random fluctuation caught at a peak of benefit.
Despite the landmark status of CREDENCE, what are the primary limitations regarding its external validity (generalizability) for the total population of patients with chronic kidney disease?
Key Response
The trial strictly included patients with albuminuric CKD (UACR 300-5000 mg/g) and Type 2 Diabetes. This leaves questions about the efficacy of canagliflozin in 'non-proteinuric' diabetic kidney disease (a growing phenotype) and non-diabetic CKD etiologies (such as IgA nephropathy or hypertensive nephrosclerosis). Furthermore, the exclusion of patients with recent immunosuppressive therapy for glomerular disease limits its application in the glomerulonephritis population.
Based on the CREDENCE data, should SGLT2 inhibitors be elevated to a Level 1A recommendation for patients with Type 2 Diabetes and CKD, and how does this compare to the 2019/2020 KDIGO and ADA standards?
Key Response
CREDENCE provided the definitive evidence needed to upgrade SGLT2 inhibitors to a Grade A, Level 1 recommendation. Current KDIGO guidelines now recommend an SGLT2i as first-line therapy (alongside metformin) for patients with T2DM and CKD with an eGFR ≥20 mL/min/1.73m². This reflects a transition from seeing SGLT2is as third-line glucose-lowering agents to foundational 'disease-modifying' therapies for renal preservation.
Clinical Landscape
Noteworthy Related Trials
EMPA-REG OUTCOME
Tested
Empagliflozin 10mg or 25mg daily
Population
T2DM patients with established cardiovascular disease
Comparator
Placebo
Endpoint
3-point MACE (CV death, nonfatal MI, nonfatal stroke)
CANVAS Program
Tested
Canagliflozin 100mg or 300mg daily
Population
T2DM patients at high cardiovascular risk
Comparator
Placebo
Endpoint
3-point MACE
DAPA-CKD
Tested
Dapagliflozin 10mg daily
Population
Patients with CKD (eGFR 25-75) with or without T2DM
Comparator
Placebo
Endpoint
Composite of sustained eGFR decline >=50%, ESRD, or renal/CV death
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis